http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114249773-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F15-0093 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-282 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-555 |
| filingDate | 2021-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114249773-B |
| titleOfInvention | Tetravalent platinum compound releasing nitric oxide and its preparation and application |
| abstract | The invention belongs to the field of biomedicine, and specifically relates to a tetravalent platinum compound releasing nitric oxide and its preparation and application. The nitric oxide donor molecule is coupled to a tetravalent platinum drug to prepare a tetravalent platinum compound releasing nitric oxide. Platinum-based chemotherapeutic drugs, which have significant anti-tumor therapeutic effects: Nitric oxide has the function of immunoregulation, which significantly enhances the anti-tumor immune response induced by platinum-based drugs; at the same time, platinum-based anti-tumor drugs are mainly excreted from the kidney , causing kidney damage, tetravalent platinum-based chemotherapy drugs that release nitric oxide reduce the damage of platinum-based drugs to the kidney and reduce the nephrotoxicity of the drug. |
| priorityDate | 2021-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 39.